Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia

Heike Pfeifer,Barbara Wassmann,Wolfgang Bethge,Jolanta Dengler,M Bornhauser,Michael Stadler,Dietrich W. Beelen,Vladan Vucinic,Thomas Burmeister,M. Stelljes,Christoph Faul,Peter Dreger,Alexander Kiani,Kerstin Schäfer-Eckart,Rainer Schwerdtfeger,Ethan M. Lange,B. Kubuschok,Heinz-August Horst,Martin Gramatzki,Patrick Brück,Hubert Serve,Dieter Hoelzer,Gökbuget N,Oliver G. Ottmann

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia

2013

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1- positive acute lymphoblastic leukemia

Keywords:

Cancer research
Minimal residual disease
Stem cell
ABL
Imatinib
Lymphoblastic Leukemia
Transplantation
Medicine
breakpoint cluster region
Internal medicine
Surgery
Tolerability
Survival analysis
Multicenter trial
Discontinuation
imatinib mesylate
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

159

Citations